Precision medicine aims to provide highly specific treatments tailored to each individual, combining advanced genetic sequencing, big-data analytics, and supercomputing. It recognises that two patients with the same disease may respond differently due to genetic and biological differences. Shenzhen-based MGI is at the forefront, developing sequencing and automation technologies to empower healthcare professionals with better data for improved patient outcomes.
Genomic sequencing has advanced dramatically: what once took 13 years and US$3.8 billion can now be completed in a day for US$500. MGI’s population-scale sequencing technologies support national genome programmes worldwide and contribute to projects like the Million Microbiome of Humans Project, which aims to sequence and analyse one million human microbiome samples to enhance precision medicine.
MGI’s high-throughput sequencers, including DNBSEQ-G400 and DNBSEQ-T7, have advanced oncology, cardiovascular testing, and infectious disease monitoring. Its laboratory automation systems streamline genome sequencing, while robotic ultrasound devices extend precision diagnostics to remote regions, enabling accurate, real-time telemedicine.
MGI also collaborates with partners such as Singapore-based Nalagenetics to lower technical and financial barriers, making advanced precision-medicine tools more accessible. Through innovation and collaboration, MGI continues to drive the development of precision medicine globally.
StandardMPS and CoolMPS sequencing reagents and sequencers may not be available in certain countries; HotMPS sequencing reagents are only available in select regions.
